Dr. Nigel Stevenson from Exubrion
Therapeutics® and Vivos Inc. CEO and President Dr. Mike Korenko have submitted a joint abstract entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and
Osteoarthritis” to the 11th International Conference on Isotopes on July 23-24 in Saskatoon Canada.
Nigel is Exubrion Therapeutics’ Chief Operations Officer and is also the Vivos Inc. Chief Science Advisor. The two companies co-operate since they are in totally different therapy markets. The
executives of both companies decided that it is in their best interest to promote the benefits of precision radionuclide therapy.